Gain Therapeutics, Inc. cash flow to debt ratio of -2.52K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Gain Therapeutics, Inc.'s free cash flow has increased -2.28% from $-18.90M last year to $-18.47M, signaling increasing performance

Gain Therapeutics, Inc.'s debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability.

Gain Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.09 last year to 0.05 today, signaling strengthened financials

Gain Therapeutics, Inc. has a net cash position, so leverage is healthy.

Gain Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Gain Therapeutics, Inc. has insufficient data to evaluate this check.

Gain Therapeutics, Inc.'s short-term assets of $22.24M exceed its short-term liabilities of $3.35M

Gain Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Gain Therapeutics, Inc.'s return on equity of -201.43%, is lower than 15.00%, indicating bad performance

Gain Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Gain Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Gain Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Gain Therapeutics, Inc. has negative free cash flow, indicating cash burn

Gain Therapeutics, Inc.'s yearly earnings has increased -1.23% since last year from $-20.41M to $-20.16M, signaling increasing performance

Gain Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -130.70% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Gain Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Gain Therapeutics, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Gain Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Gain Therapeutics, Inc. has insufficient data to evaluate this check.

Gain Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Gain Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Gain Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Gain Therapeutics, Inc. has insufficient data to evaluate this check.

Gain Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Gain Therapeutics, Inc. has a price-to-book ratio of 5.34x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Gain Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue